Cytosorbents Corporation — Q1 2012 Form 10-Q
Business context and period: Development-stage medical-device company; results cover the three months ended March 31, 2012, compared with Q1 2011. CytoSorb had CE Mark approval for EU sales, but the company had not begun full commercial operations. Initial sales were in a limited test-market phase.
Financial results and position
| Metric | Q1 2012 | Q1 2011 / prior date |
|---|---|---|
| Revenue | $16,893 | $0 |
| Cost of goods sold / gross profit | $10,080 / $6,813 | $0 / $0 |
| Gross margin | Approximately 40% | Not applicable |
| Operating loss | $(1,067,226) | $(1,128,491) |
| Net loss | $(1,426,596) | $(1,214,584) |
| Net loss available to common shareholders | $(2,090,513) | $(1,956,229) |
| Net cash used in operations | $(1,072,325) | $(587,954) |
| Cash from financing activities | $1,700,001 | $1,968,750 |
| Cash and cash equivalents | $1,803,049 at March 31 | $1,186,653 at December 31, 2011 |
| Current assets / current liabilities | $2,358,470 / $2,248,818 | At March 31, 2012 |
| Convertible notes, net of discount | $1,147,323 current; no long-term balance | $294,323 current and $276,250 long-term at December 31, 2011 |
Q1 operating expenses were $1.074 million, down from $1.128 million. Research and development expense declined 15.3% to $643,281; legal, financial and consulting expense increased 62.5% to $161,292; general and administrative expense was nearly unchanged at $269,466. Net interest expense rose to $359,370 from $86,093, primarily due to non-cash amortization of debt discount. The company recorded $663,917 in preferred-stock dividends, increasing the loss attributable to common shareholders. Working capital was approximately $109,652 at quarter-end. Q1 investing cash use was $11,280.
Changes, financing, and outlook
- Revenue began in Q1 2012 through limited EU test-market sales; management expected modest sales until broader marketing expansion.
- Operating loss narrowed year over year, but net loss and operating cash use increased, reflecting higher interest expense and other changes.
- The company issued $700,000 of 12-month notes at 8% interest, convertible at $0.15 per share, with warrants exercisable at $0.175. During the quarter, $395,154 of notes and accrued interest converted into common stock.
- The Lincoln Park Capital agreement provided up to $8.5 million of potential equity purchases over 32 months, subject to conditions, including a $0.10 minimum share price. The company received approximately $1 million under the agreement in Q1. It reported approximately $650,000 of additional proceeds from April–May sales, after quarter-end.
- Management said cash was expected to fund operations into the third quarter of 2012; additional financing would be needed to continue clinical studies and commercialization. It was hiring a European sales team, transitioning from controlled marketing toward a German product introduction, and evaluating distributors in other approved markets. No specific financial guidance was provided.
- The company reported CE Mark approval and described clinical-trial results as showing a 30–50% reduction in key cytokines; it also reported no serious device-related adverse events in more than 300 human treatments. These are company-reported findings, not a guarantee of commercial or regulatory success.
Risks, contingencies, and unusual items
The filing states that substantial doubt exists about the company’s ability to continue as a going concern: it had incurred negative operating cash flows since inception, accumulated a $94.6 million development-stage deficit, and depended on future financing. Management cautioned that financing might not be available on acceptable terms or in sufficient amounts; absent adequate funds, programs or commercialization could be delayed, reduced, or stopped.
Other cited risks include market acceptance, manufacturing and commercialization execution, clinical and product-liability risks, competition, regulatory compliance, and obtaining FDA approval for US sales. CE Mark approval does not assure FDA approval. Potential patent litigation could trigger warrants for up to 10 million common shares under an agreement; no such litigation had arisen through March 31, 2012, and no liability was recorded. The company also disclosed royalty obligations on product sales. It reported no material off-balance-sheet arrangements and no material changes to internal control over financial reporting.
Important facts for investors to verify
- Whether cash and subsequent LPC proceeds provided adequate runway, and the availability and terms of additional financing.
- Whether EU sales expanded beyond the limited test-market phase and whether revenue growth supported commercialization costs.
- The composition and terms of convertible debt, warrants, preferred-stock dividends, and potential dilution; common shares outstanding were 189.8 million at March 31 and 194.9 million as of May 14, 2012.
- Clinical evidence, product safety and effectiveness, manufacturing readiness, and the regulatory pathway and costs for any US launch.
- Whether the patent-litigation warrant contingency or other royalty and contractual obligations changed after the reporting date.